JP7474239B2 - 架橋ヒドロゲルの動的濾過の方法 - Google Patents
架橋ヒドロゲルの動的濾過の方法 Download PDFInfo
- Publication number
- JP7474239B2 JP7474239B2 JP2021505428A JP2021505428A JP7474239B2 JP 7474239 B2 JP7474239 B2 JP 7474239B2 JP 2021505428 A JP2021505428 A JP 2021505428A JP 2021505428 A JP2021505428 A JP 2021505428A JP 7474239 B2 JP7474239 B2 JP 7474239B2
- Authority
- JP
- Japan
- Prior art keywords
- biopolymer
- gel
- diafiltration
- based hydrogel
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims description 68
- 238000000034 method Methods 0.000 title claims description 52
- 238000001914 filtration Methods 0.000 title claims description 39
- 239000000499 gel Substances 0.000 claims description 107
- 229920002674 hyaluronan Polymers 0.000 claims description 39
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 38
- 238000011026 diafiltration Methods 0.000 claims description 38
- 229960003160 hyaluronic acid Drugs 0.000 claims description 38
- 229920001222 biopolymer Polymers 0.000 claims description 29
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical group C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 claims description 28
- 238000012545 processing Methods 0.000 claims description 14
- 239000000872 buffer Substances 0.000 claims description 13
- 239000004971 Cross linker Substances 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 7
- 229960004194 lidocaine Drugs 0.000 claims description 7
- 229920006037 cross link polymer Polymers 0.000 claims description 3
- 239000003193 general anesthetic agent Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000005086 pumping Methods 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000000919 ceramic Substances 0.000 claims description 2
- 239000007857 degradation product Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 238000003860 storage Methods 0.000 description 11
- 239000007853 buffer solution Substances 0.000 description 10
- 239000012071 phase Substances 0.000 description 6
- 238000011002 quantification Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000012465 retentate Substances 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 230000002051 biphasic effect Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- -1 heparosan Chemical compound 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011035 continuous diafiltration Methods 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 2
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 229920001954 Restylane Polymers 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 206010040954 Skin wrinkling Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002316 cosmetic surgery Methods 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000011157 data evaluation Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002118 epoxides Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 229940052827 glytone Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000010813 internal standard method Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000013627 low molecular weight specie Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/731—Carrageenans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/20—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/16—Rotary, reciprocated or vibrated modules
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/34—Materials or treatment for tissue regeneration for soft tissue reconstruction
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/24—Specific pressurizing or depressurizing means
- B01D2313/243—Pumps
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/02—Rotation or turning
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/16—Diafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/02—Details relating to pores or porosity of the membranes
- B01D2325/0283—Pore size
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Biochemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dispersion Chemistry (AREA)
- Water Supply & Treatment (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Sustainable Development (AREA)
- Inorganic Chemistry (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
Description
本発明は、架橋生体高分子ベースのヒドロゲルの製造中に生成される不要な分子を除去するための改善された方法を提供するという目的に基づいている。
a)半透性フィルターディスク(複数可)を備えた動的濾過装置に架橋生体高分子ベースのヒドロゲルを移し、ゲルを透析濾過するステップであって、
i)20 1/分~500 1/分の範囲内の回転速度および0.5~6バールの範囲内の過圧を適用することによって所定の濃度までゲルを濃縮するか、または動的濾過装置の処理チャンバにゲルを直接ポンプで送るステップと、
ii)20 1/分~500 1/分の範囲内の回転速度、および0.5~6バールの範囲内の過圧を適用することによって、不要な分子を低減するために透析濾過を行うステップと、を含む、透析濾過するステップと、
b)任意選択で、非架橋ポリマー、特に非架橋ヒアルロン酸および水を含む混合物をゲルに加えるステップと、を含む。
i)真空(20~200ミリバール)下で気泡を除去するためにゲルを脱気するステップ、
ii)ゲルをシリンジに充填するステップ、
iii)オートクレーブ内で熱によりシリンジ内のゲルを滅菌するステップ、をさらに含み得る。
BDDE(例えば、WO2005/085329を参照)で架橋され、24mg/gの初期濃度を呈するヒアルロン酸ヒドロゲルを、Na2HPO4・2H2O:0,994g/L;NaH2PO4・2H2O:0.51g/L;マンニトール:42g/L、および注入用水を含む緩衝液を使用して、1:4~1:8の範囲で希釈した。希釈したゲルを容器に移し、パイプまたはチューブを介して動的濾過装置の入口に接続した。動的濾過装置は、1枚のフィルターディスク(0,034m2のフィルター面積、直径152mm、孔径7nm)、ゲル貯蔵器としての1つの容器、および緩衝液貯蔵器としての第2の容器を有する、Krauss Maffei動的クロスフローフィルターDCF152/S(Andritz AG)で構成された。両方の容器は、チューブとボールバルブを介してDCF152/Sの入口ポートに接続され、さまざまな処理ステップでそれぞれの媒体を選択した。DCF152/Sのハウジングのダブルジャケットを冷蔵サーキュレーターに接続し、ダブルジャケット内の温度を設定温度20℃に維持した。DCF152/Sの濾液を容器に集め、天秤上に置いて濾液の量を測定した。次のステップが適用された。
i)希釈したゲルを含む閉じられたゲル容器に、圧力(1.5バール)を加えてゲルを濃縮し、DCF152/Sの入口ポートへの道を開き、フィルターディスクと中空シャフトを介して濾液を除去するステップ(WO00/47312を参照)。フィルターディスクは150rpmで回転させた。ゲル中のヒアルロン酸の濃度が24mg/gになるまでゲルを濃縮した。
ii)緩衝液を含む閉じられた緩衝液容器に圧力(1.5バール)を加え、Na2HPO4・2H2O:0,994g/L;NaH2PO4・2H2O:0.51g/L;マンニトール:42g/L、および注入用水を含む緩衝溶液で透析濾過を行い、DCF 152/Sの入口ポートへの道を開き、フィルターディスクおよび中空シャフトを介して濾液を除去するステップ(WO00/47312を参照)。緩衝溶液にはリドカイン(0,27~0.33w/w%)が含まれている場合がある。別の方法として、リドカインは透析濾過後に添加され得る。フィルターディスクは150rpmで回転させた。BDDEが定量限界未満になるまでゲルを濾過した。
1.試料調製:
a.HAの酵素分解
HAは、ヒアルロニダーゼ溶液を添加し、その後粘度が低下するまでわずかに振盪させながら1~4時間インキュベートすることにより分解した。
b.BDDEの抽出
BDDEは、酢酸エチル(5%v/v)を添加し、400rpmで20分間軌道振盪させることにより、分解した試料(aで説明)から抽出した。溶液を5000rpmで10分間遠心分離させて、有機相と水相を分離した。BDDEを含む有機相をGCバイアルに移した。
2.ガスクロマトグラフ測定
a.5μLの試料(1bで説明)をGC(スプリットインジェクター、スプリット比1:5、250℃)に注入し、100℃-40℃/分-280℃の温度傾斜を使用して、および280℃で30秒間の最終保持によって、DB-1カラム(AgilentDB-1、30m、内径0.25mm、0.25μmフィルム)で分離した。検出器は、FIDを使用した。
b.データ評価は、欧州薬局方第2.2.46章に準拠した内部標準法によって実施された。
実施例1による一つの実験の結果を以下の表1に示す。
BDDE(例えば、WO2005/085329を参照)で架橋され、32~35mg/gの濃度を呈するヒアルロン酸ヒドロゲルが、動的濾過装置の処理チャンバに直接ポンプで送られた。ゲルには226.8ppmの非結合BDDEが含まれていた。動的濾過装置は、1枚のフィルターディスク(0,034m2のフィルター面積、直径152mm、孔径5nm)、ゲル貯蔵器としての1つの容器、および緩衝液貯蔵器としての第2の容器を有するKrauss Maffei動的クロスフローフィルターDCF 152/S(Andritz AG)で構成された。両方の容器は、チューブとボールバルブを介してDCF 152/Sの入口ポートに接続され、さまざまな処理ステップでそれぞれの媒体を選択するようにした。DCF 152/Sのハウジングのダブルジャケットを冷蔵サーキュレーターに接続し、ダブルジャケット内の温度を設定温度20℃に維持した。DCF 152/Sの濾液を容器に集め、天秤上に置いて濾液の量を測定した。次のステップが適用された。
i)緩衝液を含む閉じられた緩衝液容器に圧力(1.5バール)を加え、Na2HPO4・2H2O:5,96g/L;NaH2PO4・2H2O:2,57g/L;NaCl:2,29g/L、および注入用水を含む緩衝溶液で透析濾過を行い、DCF152/Sの入口ポートへの道を開き、フィルターディスクおよび中空シャフトを介して濾液を除去するステップ(WO00/47312を参照)。緩衝溶液には、リドカイン(0,27~0.33w/w%)が含まれている場合がある。別の方法として、リドカインは透析濾過後に添加され得る。フィルターディスクを150rpm(1/分)で回転させた。未結合のBDDEが定量限界(LOQ)未満になるまで、ゲルを濾過した。BDDEの量は、上で説明したように測定された(実施例1を参照)。動的濾過処理は2時間1分以内に実施された。
さらなる実験の結果を次の表2に示す。
実施例3は、上記の実施例2に従って実施されたが、使用された動的濾過装置は、(実施例1および実施例2のように1枚ではなく)6枚のフィルターディスク(フィルター面積0,034m2、直径152mm、孔径5nm)を有するKrauss Maffei動的クロスフローフィルターDCF 152/S(Andritz AG)である点が異なる。BDDE(例えば、WO2005/085329を参照)で架橋され、66mg/gの濃度を呈するヒアルロン酸ヒドロゲルを、実施例1および実施例2に記載の緩衝溶液を使用してファクター1:2で希釈した。約33mg/gの濃度を有するヒアルロン酸ヒドロゲルを、動的濾過装置の処理チャンバに直接ポンプで送った。ゲルには226.8ppmの非結合BDDEが含まれていた。
ゲルのBDDE:最初のBDDE含量
DCFのBDDE:濾過後のヒドロゲルの最終のBDDE含量
Claims (15)
- 化学架橋剤によって架橋された構造を有する生体高分子系ヒドロゲルの動的濾過の方法であって、
5nm~2μmの孔径を有する1~10枚の回転式の半透性中空フィルターディスクを有する処理チャンバ、該処理チャンバに接続されるゲル貯蔵器及び緩衝液貯蔵器を備えた動的濾過装置を使用し、
下記のステップi)及びステップii)を含み、
ステップi)前記ゲル貯蔵器に0.5~6バールの過圧を適用して前記生体高分子系ヒドロゲルを前記処理チャンバに移送し、回転速度が20 1/分~500 1/分の前記半透性中空フィルターディスクを用いることにより、前記生体高分子系ヒドロゲルを10~70mg/gの濃度まで濃縮するか、または、前記処理チャンバに10~70mg/gの濃度の前記生体高分子系ヒドロゲルをポンプで直接移送するステップ、
ステップii)前記緩衝液貯蔵器に0.5~6バールの過圧を適用して緩衝液を前記処理チャンバに移送し、濾液が生成するのと同じ速度で前記処理チャンバに緩衝液を加えつつ、回転速度が20 1/分~500 1/分の前記半透性中空フィルターディスクを用いることにより透析濾過を行い、未反応の化学架橋剤及びその分解生成物を減らすステップ、
前記生体高分子系ヒドロゲルがヒアルロン酸、ヘパロサン、それらの塩若しくは誘導体、又はそれらの組み合わせから作られ、
前記化学架橋剤が1,4-ブタンジオールジグリシジルエーテル(BDDE)である、方法。 - 前記方法が、非架橋ポリマー及び水を含む混合物を前記生体高分子系ヒドロゲルに添加するステップを更に含む、請求項1記載の方法。
- 前記非架橋ポリマーが非架橋ヒアルロン酸である、請求項2記載の方法。
- 前記半透性中空フィルターディスクが、30nm~600nmの孔径を有する、請求項1記載の方法。
- 前記半透性中空フィルターディスクが、80nm~300nmの孔径を有する、請求項1記載の方法。
- 前記半透性中空フィルターディスクが、5nm~60nmの孔径を有する、請求項1記載の方法。
- 前記半透性中空フィルターディスクがセラミック、金属、またはポリマー材料で作られる、請求項1~6のいずれか一項に記載の方法。
- 前記生体高分子系ヒドロゲルがヒアルロン酸から作られており、ステップii)における前記透析濾過が、20 1/分~500 1/分の範囲内の回転速度、および0.5~3バールの範囲内の圧力を適用することによって実施され、ステップii)における前記透析濾過が、10~70mg/gの範囲の前記生体高分子系ヒドロゲルの濃度で実施される、請求項1~7のいずれか一項に記載の方法。
- 透析濾過中または透析濾過後に麻酔剤が前記生体高分子系ヒドロゲルに添加される、請求項1~8のいずれか一項に記載の方法。
- 透析濾過中または透析濾過後にリドカインが前記生体高分子系ヒドロゲルに添加される、請求項9に記載の方法。
- ステップii)における前記透析濾過が、60℃~70℃の範囲の温度で、2~4時間実施される、請求項1~10のいずれか一項に記載の方法。
- ステップii)における前記透析濾過及び前記ステップi)が、60℃~70℃の範囲の温度で、2~4時間の時間実施される、請求項1~11のいずれか一項に記載の方法。
- 前記生体高分子系ヒドロゲルが、2~30分の保持時間の間、121℃~135℃で前記動的濾過装置内で滅菌される、請求項1~12のいずれか一項に記載の方法。
- 前記ステップi)及び前記ステップii)が、10時間未満で行われる、請求項1~13のいずれか一項に記載の方法。
- 前記ステップi)及び前記ステップii)が、5時間未満で行われる、請求項14記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPPCT/EP2018/071328 | 2018-08-07 | ||
EP2018071328 | 2018-08-07 | ||
PCT/EP2019/071096 WO2020030629A1 (en) | 2018-08-07 | 2019-08-06 | Method for dynamic filtration of a cross-linked hydrogel |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021533975A JP2021533975A (ja) | 2021-12-09 |
JP7474239B2 true JP7474239B2 (ja) | 2024-04-24 |
Family
ID=63143145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021505428A Active JP7474239B2 (ja) | 2018-08-07 | 2019-08-06 | 架橋ヒドロゲルの動的濾過の方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210299335A1 (ja) |
EP (1) | EP3833695A1 (ja) |
JP (1) | JP7474239B2 (ja) |
KR (1) | KR20210041562A (ja) |
CN (1) | CN112533960B (ja) |
AU (1) | AU2019319024B2 (ja) |
BR (1) | BR112021001515A2 (ja) |
CA (1) | CA3108125A1 (ja) |
IL (1) | IL280439A (ja) |
MX (1) | MX2021001208A (ja) |
SG (1) | SG11202101017SA (ja) |
WO (1) | WO2020030629A1 (ja) |
ZA (1) | ZA202100068B (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202317214A (zh) | 2021-06-23 | 2023-05-01 | 德商莫茲製藥有限兩合公司 | 以絲蛋白交聯多醣及所得材料之用途 |
EP4362993A1 (en) | 2021-06-30 | 2024-05-08 | Merz Pharma GmbH & Co. KGaA | Hyaluronic acid dermal fillers crosslinked with polyethylene glycol diglycidyl ether, method for making same and uses thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005112888A8 (en) | 2004-05-20 | 2007-01-04 | Mentor Corp | Methods for making injectable polymer hydrogels |
JP2007519779A (ja) | 2003-12-30 | 2007-07-19 | ジェンザイム コーポレイション | 架橋したヒアルロナンおよび/またはハイランに由来する粘着性ゲル、その調製および使用法 |
JP2011529762A (ja) | 2008-08-04 | 2011-12-15 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ | 麻酔剤を含有するヒアルロン酸系ゲル |
JP2015526537A (ja) | 2012-06-15 | 2015-09-10 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アウフ アクティーン | ヒアルロン酸に基づく組成物の調製方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60194960A (ja) * | 1984-03-17 | 1985-10-03 | テルモ株式会社 | 体液濾過装置 |
US5143724A (en) | 1990-07-09 | 1992-09-01 | Biomatrix, Inc. | Biocompatible viscoelastic gel slurries, their preparation and use |
US5679249A (en) * | 1991-12-24 | 1997-10-21 | Pall Corporation | Dynamic filter system |
AT406936B (de) | 1999-02-08 | 2000-10-25 | Andritz Patentverwaltung | Verfahren und vorrichtung zur querstromfiltration |
FR2861734B1 (fr) | 2003-04-10 | 2006-04-14 | Corneal Ind | Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus |
FR2865737B1 (fr) | 2004-02-03 | 2006-03-31 | Anteis Sa | Gel reticule biocompatible |
US20100035838A1 (en) | 2006-09-19 | 2010-02-11 | Geoffrey Kenneth Heber | Cross-linked polysaccharide gels |
FR2909560B1 (fr) | 2006-12-06 | 2012-12-28 | Fabre Pierre Dermo Cosmetique | Gel d'acide hyaluronique pour injection intradermique |
EP2222715B1 (en) | 2007-12-19 | 2019-07-24 | Evonik Degussa GmbH | Crosslinked hyaluronic acid in emulsion |
ITMI20072416A1 (it) * | 2007-12-21 | 2009-06-22 | Sigea Srl | Derivati polisaccaridici dell'acido lipoico, loro preparazione ed uso come dermocosmetici e presidi medicali |
FR2938187B1 (fr) | 2008-11-07 | 2012-08-17 | Anteis Sa | Composition injectable a base d'acide hyaluronique ou l'un de ses sels, de polyols et de lidocaine, sterilisee a la chaleur |
EP2413894B1 (en) | 2009-04-02 | 2017-01-04 | Allergan, Inc. | Hair-like shaped hydrogels for soft tissue augmentation |
CN102399295B (zh) * | 2010-09-09 | 2013-11-06 | 常州百瑞吉生物医药有限公司 | 低巯基化改性度生物相容高分子巯基化衍生物及其交联材料和用途 |
PT2637710T (pt) | 2010-11-08 | 2017-07-12 | Allergan Ind Sas | Formulações à base de ácido hialurónico |
US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
FR2997085B1 (fr) | 2012-10-24 | 2015-05-29 | Teoxane | Procede de preparation d'un gel reticule |
RU2582702C1 (ru) * | 2015-08-19 | 2016-04-27 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) | Способ получения композиции на основе модифицированного гиалуроната натрия, композиция на основе модифицированного гиалуроната натрия и ее применение |
US20180326375A1 (en) * | 2015-09-01 | 2018-11-15 | Merz Pharma Gmbh & Co. Kgaa | Method of making a cross-linked polymer gel and device for performing the method |
US11324854B2 (en) * | 2017-11-17 | 2022-05-10 | Altergon Sa | Resorbable implantable device based on crosslinked glycosaminoglycans, and process for the preparation thereof |
-
2019
- 2019-08-06 WO PCT/EP2019/071096 patent/WO2020030629A1/en active Application Filing
- 2019-08-06 KR KR1020217003173A patent/KR20210041562A/ko unknown
- 2019-08-06 US US17/263,973 patent/US20210299335A1/en active Pending
- 2019-08-06 EP EP19746507.3A patent/EP3833695A1/en active Pending
- 2019-08-06 AU AU2019319024A patent/AU2019319024B2/en active Active
- 2019-08-06 SG SG11202101017SA patent/SG11202101017SA/en unknown
- 2019-08-06 CA CA3108125A patent/CA3108125A1/en active Pending
- 2019-08-06 BR BR112021001515-9A patent/BR112021001515A2/pt active Search and Examination
- 2019-08-06 CN CN201980050070.9A patent/CN112533960B/zh active Active
- 2019-08-06 JP JP2021505428A patent/JP7474239B2/ja active Active
- 2019-08-06 MX MX2021001208A patent/MX2021001208A/es unknown
-
2021
- 2021-01-05 ZA ZA2021/00068A patent/ZA202100068B/en unknown
- 2021-01-27 IL IL280439A patent/IL280439A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007519779A (ja) | 2003-12-30 | 2007-07-19 | ジェンザイム コーポレイション | 架橋したヒアルロナンおよび/またはハイランに由来する粘着性ゲル、その調製および使用法 |
WO2005112888A8 (en) | 2004-05-20 | 2007-01-04 | Mentor Corp | Methods for making injectable polymer hydrogels |
JP2011529762A (ja) | 2008-08-04 | 2011-12-15 | アラーガン・アンデュストリー・ソシエテ・パール・アクシオン・サンプリフィエ | 麻酔剤を含有するヒアルロン酸系ゲル |
JP2015526537A (ja) | 2012-06-15 | 2015-09-10 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト アウフ アクティーン | ヒアルロン酸に基づく組成物の調製方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20210041562A (ko) | 2021-04-15 |
SG11202101017SA (en) | 2021-02-25 |
MX2021001208A (es) | 2021-06-15 |
CA3108125A1 (en) | 2020-02-13 |
CN112533960A (zh) | 2021-03-19 |
IL280439A (en) | 2021-03-01 |
CN112533960B (zh) | 2022-12-27 |
BR112021001515A2 (pt) | 2021-04-27 |
US20210299335A1 (en) | 2021-09-30 |
EP3833695A1 (en) | 2021-06-16 |
JP2021533975A (ja) | 2021-12-09 |
AU2019319024A1 (en) | 2021-02-18 |
ZA202100068B (en) | 2021-09-29 |
WO2020030629A1 (en) | 2020-02-13 |
AU2019319024B2 (en) | 2024-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7474239B2 (ja) | 架橋ヒドロゲルの動的濾過の方法 | |
Fissell et al. | High-performance silicon nanopore hemofiltration membranes | |
Yang et al. | Silibinin as a natural antioxidant for modifying polysulfone membranes to suppress hemodialysis-induced oxidative stress | |
KR101590666B1 (ko) | 세포 증식을 위한 조사된 멤브레인 | |
US20090269323A1 (en) | Non-amphiphile-based water-in-water emulsion and uses thereof | |
TW200932330A (en) | Protein purification method | |
US9901601B2 (en) | Method for preparing decellularized tissue product, and graft provided with decellularized tissue product | |
JP7388722B2 (ja) | アルギン酸中空マイクロファイバ | |
JP2007231225A (ja) | エンドトキシン含有量を低減したゼラチンの製造方法および低エンドトキシンゼラチン | |
Ter Beek et al. | New membranes based on polyethersulfone–SlipSkin™ polymer blends with low fouling and high blood compatibility | |
Fu et al. | Synthesis and biocompatibility of an argatroban-modified polysulfone membrane that directly inhibits thrombosis | |
JP2004305840A (ja) | 中空糸膜の保存方法 | |
JPH1099431A (ja) | 体外循環により血液を処理する装置およびその製造方法 | |
Chiang et al. | Nonsolvent-induced phase separation preparation of porous TOPO-mixed polyethersulfone membranes for selective clearance of p-cresol from simulated serum | |
JP2005224604A (ja) | 血液浄化膜およびそれを用いた血液浄化器 | |
Bakhshayeshi et al. | Effect of solution pH on protein transmission and membrane capacity during virus filtration | |
KR20130124798A (ko) | 합성 고분자, 폴리사카라이드 및 단백질을 포함하는 크라이오젤 스캐폴드 및 상기 스캐폴드를 이용한 조직 재생방법 | |
RU2803656C2 (ru) | Способ динамической фильтрации поперечно-сшитого гидрогеля | |
WO2018020285A4 (en) | Flow capture device and method for removing cells from blood | |
CN115337473B (zh) | 一种用于体外膜肺氧合系统气体交换膜的血液相容性涂层及其制备方法和应用 | |
Qin et al. | Improving the Blood Compatibility and the Gas Permeability of Polyether Ether Ketone Hollow Fiber Membrane Used for Membrane Oxygenator via Grafting Hydrophilic Components | |
KR102181502B1 (ko) | 에피갈로카테킨 갈레이트가 코팅된 고분자 복합체의 제조방법 및 상기 방법에 따라 제조된 고분자 복합체 | |
Prihandana et al. | REVIEW OF SURFACE MODIFICATION OF NANOPOROUS POLYETHERSULFONE MEMBRANE AS A DIALYSIS MEMBRANE. | |
Voicu et al. | Cellulose derivatives based membranes for biomedical applications | |
JP4017958B2 (ja) | 細胞培養担体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220509 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230427 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231018 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240305 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240329 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240412 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7474239 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |